Search
DSP107
go.drugbank.com/drugs/DB17501InvestigationalDSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigational[L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators. … [A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521]
Categories: Antineoplastic and Immunomodulating AgentsEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational, and large cell carcinoma. … received an ALK-inhibitor on December 18, 2024.
Willardiine
go.drugbank.com/drugs/DB04129ExperimentalWillardiine is a compound isolated from seeds of _Acacia willariana_.
Categories: Amino Acids, Peptides, and ProteinsAlbinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalIn response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Categories: MATE 2-K InhibitorsLatrunculin A
go.drugbank.com/drugs/DB02621InvestigationalLatrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer. … It disrupts actin polymerization, prevents mitotic spindle formation and thus cell replication.
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalPGX-100 is an intravenous dosage form of modified heparin. … It is developed for treatment of exacerbation of obstructive pulmonary disease (COPD) and for the prevention and treatment of cardiac ischemia reperfusion injury (following acute myocardial infarction
Tagatose
go.drugbank.com/drugs/DB04936InvestigationalAdditionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes. … It is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener.
Tetraethylammonium
go.drugbank.com/drugs/DB08837InvestigationalIts mechanism of action is still being investigated, but it is known that tetraethylammonium blocks autonomic ganglia, calcium- and voltage- activated potassium channels, and nicotinic acetylcholine receptors … As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide.